Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 1
2006 2
2008 2
2009 1
2010 3
2011 1
2012 1
2013 5
2016 2
2018 2
2019 1
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics of Isoniazid-induced Rhabdomyolysis in a Girl.
Kurane K, Goto M, Sano K, Noguchi K, Tamura D, Yamagata T. Kurane K, et al. Among authors: sano k. Intern Med. 2018 Dec 1;57(23):3501-3502. doi: 10.2169/internalmedicine.1341-18. Epub 2018 Jul 6. Intern Med. 2018. PMID: 29984757 Free PMC article. No abstract available.
Effect of Radiological Countermeasures on Subjective Well-Being and Radiation Anxiety after the 2011 Disaster: The Fukushima Health Management Survey.
Murakami M, Takebayashi Y, Takeda Y, Sato A, Igarashi Y, Sano K, Yasutaka T, Naito W, Hirota S, Goto A, Ohira T, Yasumura S, Tanigawa K. Murakami M, et al. Among authors: sano k. Int J Environ Res Public Health. 2018 Jan 12;15(1):124. doi: 10.3390/ijerph15010124. Int J Environ Res Public Health. 2018. PMID: 29329263 Free PMC article.
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, Ikeda T, Yamaguchi H, Nakatomi K, Fukuda M, Izumikawa K, Mukae H. Mizoguchi K, et al. Among authors: sano k. Cancer Chemother Pharmacol. 2016 Aug;78(2):377-82. doi: 10.1007/s00280-016-3097-4. Epub 2016 Jun 23. Cancer Chemother Pharmacol. 2016. PMID: 27339148 Clinical Trial.
Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Motoshima K, Nakamura Y, Sano K, Ikegami Y, Ikeda T, Mizoguchi K, Takemoto S, Fukuda M, Nagashima S, Iida T, Tsukamoto K, Kohno S. Motoshima K, et al. Among authors: sano k. Cancer Chemother Pharmacol. 2013 Dec;72(6):1299-1304. doi: 10.1007/s00280-013-2307-6. Cancer Chemother Pharmacol. 2013. PMID: 24121455 Clinical Trial.
27 results